You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePalmitic Acid
Accession NumberDB03796  (EXPT01393, EXPT02607)
TypeSmall Molecule
GroupsExperimental
DescriptionA common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids. [PubChem]
Structure
Thumb
Synonyms
1-Hexyldecanoic Acid
1-Pentadecanecarboxylic acid
FAT
Hexadecanoate
Hexadecanoic acid
Hexadecoic acid
Hexadecylic acid
Hexaectylic acid
Palmitate
Palmitinic acid
Palmitinsaeure
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Levovist - Pws IV (4g Granules /vial)Berlex Canada Inc.
Sha-lemShalem Products, Inc.
SaltsNot Available
Categories
UNII2V16EO95H1
CAS number57-10-3
WeightAverage: 256.4241
Monoisotopic: 256.240230268
Chemical FormulaC16H32O2
InChI KeyIPCSVZSSVZVIGE-UHFFFAOYSA-N
InChI
InChI=1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)
IUPAC Name
hexadecanoic acid
SMILES
CCCCCCCCCCCCCCCC(O)=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsPalmitic acid is the first fatty acid produced during lipogenesis (fatty acid synthesis) and from which longer fatty acids can be produced. Palmitate negatively feeds back on acetyl-CoA carboxylase (ACC) which is responsible for converting acetyl-ACP to malonyl-ACP on the growing acyl chain, thus preventing further palmitate generation
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
RhodopsinProteinunknownNot AvailableHumanP08100 details
SEC14-like protein 2ProteinunknownNot AvailableHumanO76054 details
Palmitoyl-protein thioesterase 1ProteinunknownNot AvailableHumanP50897 details
Myelin P2 proteinProteinunknownNot AvailableHumanP02689 details
GlycodelinProteinunknownNot AvailableHumanP09466 details
Hepatocyte nuclear factor 4-gammaProteinunknownNot AvailableHumanQ14541 details
Lipid binding proteinProteinunknownNot AvailableGeobacillus stearothermophilusP83812 details
Cytochrome P450 2C8ProteinunknownNot AvailableHumanP10632 details
Trafficking protein particle complex subunit 3ProteinunknownNot AvailableHumanO43617 details
Fatty acid-binding protein TM_1468ProteinunknownNot AvailableThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)Q9X1H9 details
Alpha-lactalbuminProteinunknownNot AvailableHumanP00709 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityAcute oral toxicity (LD50) in rat is >10000 mg/kg
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Glycerolipid MetabolismMetabolicSMP00039
Alendronate Action PathwayDrug actionSMP00095
Zoledronate Action PathwayDrug actionSMP00107
Cerebrotendinous Xanthomatosis (CTX)DiseaseSMP00315
Fatty Acid BiosynthesisMetabolicSMP00456
Wolman diseaseDiseaseSMP00511
Long chain acyl-CoA dehydrogenase deficiency (LCAD)DiseaseSMP00539
Fatty Acid Elongation In MitochondriaMetabolicSMP00054
Cerivastatin Action PathwayDrug actionSMP00111
Pamidronate Action PathwayDrug actionSMP00117
Atorvastatin Action PathwayDrug actionSMP00131
Cholesteryl ester storage diseaseDiseaseSMP00508
Mevalonic aciduriaDiseaseSMP00510
Trifunctional protein deficiencyDiseaseSMP00545
Rosuvastatin Action PathwayDrug actionSMP00092
Fluvastatin Action PathwayDrug actionSMP00119
Short Chain Acyl CoA Dehydrogenase Deficiency (SCAD Deficiency)DiseaseSMP00235
CHILD SyndromeDiseaseSMP00387
Hyper-IgD syndromeDiseaseSMP00509
Carnitine palmitoyl transferase deficiency (I)DiseaseSMP00538
Medium chain acyl-coa dehydrogenase deficiency (MCAD)DiseaseSMP00542
27-Hydroxylase DeficiencyDiseaseSMP00720
Pravastatin Action PathwayDrug actionSMP00089
Risedronate Action PathwayDrug actionSMP00112
Glutaric Aciduria Type IDiseaseSMP00185
Glycerol Kinase DeficiencyDiseaseSMP00187
HypercholesterolemiaDiseaseSMP00209
Congenital Bile Acid Synthesis Defect Type IIDiseaseSMP00314
Zellweger SyndromeDiseaseSMP00316
Congenital Bile Acid Synthesis Defect Type IIIDiseaseSMP00318
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Palmitic Acid.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Palmitic Acid.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Palmitic Acid.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Palmitic Acid.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Palmitic Acid.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Palmitic Acid.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Palmitic Acid.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Palmitic Acid.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Palmitic Acid.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Palmitic Acid.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Palmitic Acid.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Palmitic Acid.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Palmitic Acid.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Palmitic Acid.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palmitic Acid.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Palmitic Acid.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Palmitic Acid.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Palmitic Acid.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Palmitic Acid.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Palmitic Acid.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Palmitic Acid.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Palmitic Acid.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Palmitic Acid.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Palmitic Acid.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Palmitic Acid.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Palmitic Acid.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Palmitic Acid.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Palmitic Acid.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Palmitic Acid.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Palmitic Acid.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Palmitic Acid.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Palmitic Acid.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Palmitic Acid.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Palmitic Acid.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Palmitic Acid.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Palmitic Acid.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Palmitic Acid.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Palmitic Acid.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Palmitic Acid.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Palmitic Acid.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Palmitic Acid.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Palmitic Acid.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Palmitic Acid.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Palmitic Acid.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Palmitic Acid.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Palmitic Acid.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Palmitic Acid.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Palmitic Acid.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Palmitic Acid.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Palmitic Acid.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Palmitic Acid.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Palmitic Acid.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Palmitic Acid.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Palmitic Acid.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Palmitic Acid.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Palmitic Acid.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Palmitic Acid.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Palmitic Acid.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Palmitic Acid.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Palmitic Acid.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Palmitic Acid.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Palmitic Acid.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Palmitic Acid.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Palmitic Acid.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Palmitic Acid.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Palmitic Acid.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Palmitic Acid.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Palmitic Acid.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Palmitic Acid.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Palmitic Acid.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Palmitic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Palmitic Acid.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Palmitic Acid.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Palmitic Acid.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Palmitic Acid.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Palmitic Acid.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Palmitic Acid.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Palmitic Acid.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Palmitic Acid.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Palmitic Acid.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Palmitic Acid.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Palmitic Acid.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Palmitic Acid.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Palmitic Acid.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Palmitic Acid.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Palmitic Acid.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Palmitic Acid.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Palmitic Acid.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Palmitic Acid.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Palmitic Acid.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Palmitic Acid.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Palmitic Acid.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Palmitic Acid.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Palmitic Acid.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Palmitic Acid.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Palmitic Acid.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Palmitic Acid.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Palmitic Acid.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Palmitic Acid.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Palmitic Acid.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Palmitic Acid.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Palmitic Acid.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Palmitic Acid.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Palmitic Acid.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Palmitic Acid.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palmitic Acid.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Palmitic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Palmitic Acid.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Palmitic Acid.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Palmitic Acid.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Palmitic Acid.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Palmitic Acid.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Palmitic Acid.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Palmitic Acid.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Palmitic Acid.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Palmitic Acid.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Palmitic Acid.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Palmitic Acid.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Palmitic Acid.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Palmitic Acid.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Palmitic Acid.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Palmitic Acid.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Palmitic Acid.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Palmitic Acid.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Palmitic Acid.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Palmitic Acid.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Palmitic Acid.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Palmitic Acid.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Palmitic Acid.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Palmitic Acid.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Palmitic Acid.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Palmitic Acid.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Palmitic Acid.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Palmitic Acid.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Palmitic Acid.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Palmitic Acid.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Palmitic Acid.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Palmitic Acid.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Palmitic Acid.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Palmitic Acid.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Palmitic Acid.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Palmitic Acid.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Palmitic Acid.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Palmitic Acid.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Palmitic Acid.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Palmitic Acid.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Palmitic Acid.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Palmitic Acid.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Palmitic Acid.Experimental
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Palmitic Acid.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Palmitic Acid.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Palmitic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Palmitic Acid.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Palmitic Acid.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Palmitic Acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Palmitic Acid.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Palmitic Acid.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Palmitic Acid.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Palmitic Acid.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Palmitic Acid.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Palmitic Acid.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Palmitic Acid.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Palmitic Acid.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Palmitic Acid.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Palmitic Acid.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Palmitic Acid.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Palmitic Acid.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Palmitic Acid.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Palmitic Acid.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Palmitic Acid.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Palmitic Acid.Approved
Food InteractionsNot Available
References
Synthesis Reference

Walter R. Fehr, Earl G. Hammond, “Elevated palmitic acid production in soybeans.” U.S. Patent US5750846, issued February, 1997.

US5750846
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSDownload (73 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9888
Blood Brain Barrier+0.9488
Caco-2 permeable+0.8326
P-glycoprotein substrateNon-substrate0.6321
P-glycoprotein inhibitor INon-inhibitor0.9598
P-glycoprotein inhibitor IINon-inhibitor0.9277
Renal organic cation transporterNon-inhibitor0.9266
CYP450 2C9 substrateNon-substrate0.7886
CYP450 2D6 substrateNon-substrate0.8956
CYP450 3A4 substrateNon-substrate0.6982
CYP450 1A2 substrateInhibitor0.8326
CYP450 2C9 inhibitorNon-inhibitor0.8808
CYP450 2D6 inhibitorNon-inhibitor0.9554
CYP450 2C19 inhibitorNon-inhibitor0.9578
CYP450 3A4 inhibitorNon-inhibitor0.9484
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9647
Ames testNon AMES toxic0.9865
CarcinogenicityNon-carcinogens0.6452
BiodegradationReady biodegradable0.8795
Rat acute toxicity1.3275 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9322
hERG inhibition (predictor II)Non-inhibitor0.8868
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous
OintmentTopical
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point61.8 °CPhysProp
boiling point351.5 °CPhysProp
water solubility0.04 mg/L (at 25 °C)ROBB.ID (1966)
logP7.17SANGSTER (1993)
logS-6.81ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.000407 mg/mLALOGPS
logP7.23ALOGPS
logP6.26ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)4.95ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity77.08 m3·mol-1ChemAxon
Polarizability34.36 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.5 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)splash10-014i-0901000000-51ee83f9462d25fa4045View in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)splash10-0100-9700000000-3d8b6cf4736afa482b57View in MoNA
GC-MSGC-MS Spectrum - GC-MS (1 TMS)splash10-0159-2901000000-fb423e89a78708021db1View in MoNA
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Negative (Annotated)splash10-0a4i-0090000000-39c3a0e17432781e9760View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Negative (Annotated)splash10-0a4i-0090000000-8ec1a6953701fc22ce27View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Negative (Annotated)splash10-0fba-9200000000-23c995bf81d5ef609489View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80) , Positivesplash10-0abc-9110000000-12f1884d67998fb924a5View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-000i-0090000000-26bb4965a56ab0e82b49View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-06rj-5790000000-251700f3edf9a5af04cdView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-052f-9600000000-5b75a67e276017f221b8View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-000i-0090000000-26bb4965a56ab0e82b49View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-06rj-5790000000-251700f3edf9a5af04cdView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-052f-9600000000-5b75a67e276017f221b8View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0a4i-0090000000-e4a4200bd25f8fa480ccView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0bti-1090000000-768a48058fc0a2d7a877View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0a4l-9320000000-c9714c7ffdc804bf9323View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0a4i-0090000000-e4a4200bd25f8fa480ccView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0bti-1090000000-768a48058fc0a2d7a877View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-0a4l-9320000000-c9714c7ffdc804bf9323View in MoNA
MSMass Spectrum (Electron Ionization)splash10-06xx-9100000000-7ac9cd088cb9cb9f7560View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as long-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 13 and 21 carbon atoms.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassFatty acids and conjugates
Direct ParentLong-chain fatty acids
Alternative Parents
Substituents
  • Long-chain fatty acid
  • Straight chain fatty acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Photoreceptor activity
Specific Function:
Photoreceptor required for image-forming vision at low light intensity. Required for photoreceptor cell viability after birth. Light-induced isomerization of 11-cis to all-trans retinal triggers a conformational change leading to G-protein activation and release of all-trans retinal.
Gene Name:
RHO
Uniprot ID:
P08100
Molecular Weight:
38892.335 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Vitamin e binding
Specific Function:
Carrier protein. Binds to some hydrophobic molecules and promotes their transfer between the different cellular sites. Binds with high affinity to alpha-tocopherol. Also binds with a weaker affinity to other tocopherols and to tocotrienols. May have a transcriptional activatory activity via its association with alpha-tocopherol. Probably recognizes and binds some squalene structure, suggesting ...
Gene Name:
SEC14L2
Uniprot ID:
O76054
Molecular Weight:
46144.9 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Palmitoyl-coa hydrolase activity
Specific Function:
Removes thioester-linked fatty acyl groups such as palmitate from modified cysteine residues in proteins or peptides during lysosomal degradation. Prefers acyl chain lengths of 14 to 18 carbons.
Gene Name:
PPT1
Uniprot ID:
P50897
Molecular Weight:
34193.245 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transporter activity
Specific Function:
May play a role in lipid transport protein in Schwann cells. May bind cholesterol.
Gene Name:
PMP2
Uniprot ID:
P02689
Molecular Weight:
14909.305 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Small molecule binding
Specific Function:
This protein is, quantitatively, the main protein synthesized and secreted in the endometrium from mid-luteal phase of the menstrual cycle and during the first semester of pregnancy.
Gene Name:
PAEP
Uniprot ID:
P09466
Molecular Weight:
20624.015 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Transcription factor. Has a lower transcription activation potential than HNF4-alpha.
Gene Name:
HNF4G
Uniprot ID:
Q14541
Molecular Weight:
45876.235 Da
Kind
Protein
Organism
Geobacillus stearothermophilus
Pharmacological action
unknown
General Function:
Lipid binding
Specific Function:
Not Available
Gene Name:
Not Available
Uniprot ID:
P83812
Molecular Weight:
32173.81 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF: Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem. 2004 Mar 5;279(10):9497-503. Epub 2003 Dec 15. [PubMed:14676196 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Not Available
Specific Function:
May play a role in vesicular transport from endoplasmic reticulum to Golgi.
Gene Name:
TRAPPC3
Uniprot ID:
O43617
Molecular Weight:
20273.915 Da
Kind
Protein
Organism
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Pharmacological action
unknown
General Function:
Lipid binding
Specific Function:
Binds long-chain fatty acids, such as palmitate, and may play a role in lipid transport or fatty acid metabolism.
Gene Name:
Not Available
Uniprot ID:
Q9X1H9
Molecular Weight:
32574.335 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Lactose synthase activity
Specific Function:
Regulatory subunit of lactose synthase, changes the substrate specificity of galactosyltransferase in the mammary gland making glucose a good acceptor substrate for this enzyme. This enables LS to synthesize lactose, the major carbohydrate component of milk. In other tissues, galactosyltransferase transfers galactose onto the N-acetylglucosamine of the oligosaccharide chains in glycoproteins.
Gene Name:
LALBA
Uniprot ID:
P00709
Molecular Weight:
16224.695 Da
References
  1. Barbana C, Perez MD, Pocovi C, Sanchez L, Wehbi Z: Interaction of human alpha-lactalbumin with fatty acids: determination of binding parameters. Biochemistry (Mosc). 2008 Jun;73(6):711-6. [PubMed:18620538 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Simard JR, Zunszain PA, Hamilton JA, Curry S: Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J Mol Biol. 2006 Aug 11;361(2):336-51. Epub 2006 Jun 30. [PubMed:16844140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transporter activity
Specific Function:
Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus (By similarity).
Gene Name:
FABP4
Uniprot ID:
P15090
Molecular Weight:
14718.815 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transporter activity
Specific Function:
High specificity for fatty acids. Highest affinity for C18 chain length. Decreasing the chain length or introducing double bonds reduces the affinity. May be involved in keratinocyte differentiation.
Gene Name:
FABP5
Uniprot ID:
Q01469
Molecular Weight:
15164.36 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Oleic acid binding
Specific Function:
FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters.
Gene Name:
FABP3
Uniprot ID:
P05413
Molecular Weight:
14857.93 Da
References
  1. Zanotti G, Scapin G, Spadon P, Veerkamp JH, Sacchettini JC: Three-dimensional structure of recombinant human muscle fatty acid-binding protein. J Biol Chem. 1992 Sep 15;267(26):18541-50. [PubMed:1526991 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transporter activity
Specific Function:
FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. Binds saturated long-chain fatty acids with a high affinity, but binds with a lower affinity to unsaturated long-chain fatty acids. FABP2 may also help maintain energy homeostasis by functioning as a lipid sensor.
Gene Name:
FABP2
Uniprot ID:
P12104
Molecular Weight:
15207.165 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Konishi T, Satsu H, Hatsugai Y, Aizawa K, Inakuma T, Nagata S, Sakuda SH, Nagasawa H, Shimizu M: Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells. Br J Pharmacol. 2004 Oct;143(3):379-87. Epub 2004 Sep 6. [PubMed:15351776 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23